Posaconazole 100 Mg Tablets

POSACONAZOLE Tablet 100 mg-MSD is indicated for use in the treatment of the following fungal infections in patients 13 years of age or older:

• Oesophageal candidiasis or candidemia in patients with disease that is refractory to other appropriate antifungal agents (amphotericin B, fluconazole or itraconazole). Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
• Invasive aspergillosis in patients with disease that is refractory to amphotericin B, itraconazole or voriconazole or in patients who are intolerant of these medicinal products. Refractoriness is defined as a progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
• Fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy.
• Coccidioidomycosis.

POSACONAZOLE Tablet 100 mg-MSD is also indicated for prophylaxis of invasive fungal infections in patients who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.

Non-interchangeability between POSACONAZOLE Tablet 100 mg-MSD and NOXAFIL Oral Suspension

POSACONAZOLE Tablet 100 mg-MSD and NOXAFIL Oral Suspension are not to be used interchangeably due to the difference in the dosing of each formulation. Therefore, follow the specific dosage recommendation for each of the formulations.

Table 1: Recommended Dose for POSACONAZOLE Tablet 100 mg-MSD according to Indication

Increasing the total daily dose of oral suspension above 800 mg does not further enhance the exposure to POSACONAZOLE Tablet 100 mg-MSD.

Use in renal impairment: No dose adjustment is required for renal dysfunction and as POSACONAZOLE Tablet 100 mg-MSD is not significantly renally eliminated, an effect of severe renal insufficiency on the pharmacokinetics of POSACONAZOLE Tablet 100 mg-MSD is not expected and no dose adjustment is recommended.

Use in hepatic impairment: There are limited pharmacokinetic data in patients with hepatic insufficiency, but do not suggest that dose adjustment is necessary. In the small number of subjects studied who had hepatic insufficiency, there was an increase in half-life in subjects with decreased in hepatic function.

Use in Paediatrics: Safety and efficacy in adolescents and children below the age of 13 years have not been established.

Method of Administration

POSACONAZOLE Tablet 100 mg-MSD is intended for oral administration only. POSACONAZOLE Tablet 100 mg-MSD can be taken without regard to food. POSACONAZOLE Tablet 100 mg-MSD should be swallowed whole, and not be divided, crushed, or chewed.

POSACONAZOLE Tablet 100 mg-MSD is contraindicated in patients with known hypersensitivity to posaconazole or any component of the product.

Pregnancy and lactation

Although not studied in vitro or in vivo, co-administration of the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, and quinidine with POSACONAZOLE Tablet 100 mg-MSD are contraindicated since increased plasma concentrations of those drugs can lead to QT prolongation and occurrences of torsade de pointes. POSACONAZOLE Tablet 100 mg-MSD may increase the plasma concentrations of ergot alkaloids which may lead to ergotism. Co-administration of POSACONAZOLE Tablet 100 mg-MSD and ergot alkaloids is contraindicated. Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolised through CYP3A4 is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis. (see Section 4.5)

Hypersensitivity: There is no information regarding cross-sensitivity between POSACONAZOLE Tablet 100 mg-MSD and other azole antifungal agents. Caution should be used when prescribing POSACONAZOLE Tablet 100 mg-MSD to patients with hypersensitivity to other azoles.

Hepatic toxicity: In clinical trials, there were infrequent cases of hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin, and/or clinical hepatitis). The elevations in liver function tests were generally reversible on discontinuation of therapy and in some instances these tests normalised without drug interruption and rarely required drug discontinuation. Rarely, more severe hepatic reactions including cholestasis or hepatic failure were reported in patients with serious underlying medical conditions (e.g. haematologic malignancy) during treatment with POSACONAZOLE Tablet 100 mg-MSD.

QT prolongation: Some azoles have been associated with prolongation of QT interval. Results from a multiple time-matched ECG analysis in healthy volunteers did not show any increase in the mean of the QTc interval. Nevertheless, POSACONAZOLE Tablet 100 mg-MSD should not be administered with medications that are known to prolong QTc interval and are metabolised through CYP3A4.

Electrolyte disturbances: Especially those involving potassium, magnesium or calcium levels should be monitored and corrected as necessary before and during POSACONAZOLE Tablet 100 mg-MSD therapy.

Vincristine Toxicity: Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion and paralytic ileus. Reserve azole antifungals including posaconazole, for patients receiving a vinca alkaloid including vincristine, who have no alternative antifungal treatment options (see section 4.5).

Venetoclax Toxicity: Concomitant administration of Posaconazole with venetoclax (a CYP3A4 substrate) may increase venetoclax toxicities, including the risk of tumor lysis syndrome (TLS) and neutropenia (see 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction). Refer to the venetoclax prescribing information for detailed guidance.

Effects of other medicinal products on POSACONAZOLE Tablet 100 mg-MSD

POSACONAZOLE Tablet 100 mg-MSD is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p-glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect NOXAFIL plasma concentrations.

Rifabutin (300 mg once a day) decreased the C max (maximum plasma concentration) and AUC (area under the plasma concentration curve) of POSACONAZOLE Tablet 100 mg-MSD by 43 % and 49 % respectively. Concomitant use of POSACONAZOLE Tablet 100 mg-MSD and rifabutin should be avoided.

Phenytoin (200 mg once a day) decreased the C max and AUC of POSACONAZOLE Tablet 100 mg-MSD by 41 % and 50 %, respectively. Concomitant use of POSACONAZOLE Tablet 100 mg-MSD and phenytoin should be avoided.

H2 receptor antagonists, proton pump inhibitors (PPIs) and antacids: POSACONAZOLE Tablet 100 mg-MSD: No clinically relevant effect was observed when POSACONAZOLE Tablet 100 mg-MSD is used concomitantly with an antacid, H2 receptor antagonists and other proton pump inhibitors. No dose adjustments of POSACONAZOLE Tablet 100 mg-MSD is required when used concomitantly with these products.

Gastrointestinal Motility Agents: POSACONAZOLE Tablet 100 mg-MSD: No clinically meaningful effect on the pharmacokinetics of posaconazole was observed when POSACONAZOLE Tablet 100 mg-MSD is concomitantly administered with metoclopramide. No dosage adjustment of POSACONAZOLE Tablet 100 mg-MSDs is required when given concomitantly with metoclopramide.

Glipizide (10 mg single dose) had no clinically significant effect on POSACONAZOLE Tablet 100 mg-MSD C max and AUC. Efavirenz (400 mg once a day) decreased the C max and AUC of posaconazole by 45 % and 50 %, respectively. Concomitant use of posaconazole and efavirenz should be avoided.

Fosamprenavir: Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the C max and AUC of posaconazole (200 mg oral suspension daily on the 1st day, 200 mg oral suspension twice daily on the 2nd day, then 400 mg oral suspension twice daily x 8 Days) by 21 % and 23 %, respectively.

Effects of POSACONAZOLE Tablet 100 mg-MSD on other medicinal products

POSACONAZOLE Tablet 100 mg-MSD is not metabolised to a clinically significant extent through the cytochrome P450 system. However, POSACONAZOLE Tablet 100 mg-MSD is an inhibitor of CYP3A4 and thus the plasma levels of drugs that are metabolised through this enzyme pathway may increase when administered with POSACONAZOLE Tablet 100 mg-MSD.

Ergot alkaloids: NOXAFIL may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism. Co-administration of POSACONAZOLE Tablet 100 mg-MSD and ergot alkaloids is contra-indicated. (see section 4.3)

Vinca alkaloids: Most of the vinca alkaloids (e.g., vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

Ciclosporin: In heart transplant patients on stable doses of ciclosporin, POSACONAZOLE Tablet 100 mg-MSD 200 mg once daily increased ciclosporin concentrations requiring dose reductions. When initiating treatment with POSACONAZOLE Tablet 100 mg-MSD in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three fourths of the current dose). Thereafter blood levels of ciclosporin should be monitored carefully during co-administration and upon discontinuation of POSACONAZOLE Tablet 100 mg-MSD treatment, the dose of ciclosporin should be adjusted as necessary.

Tacrolimus: POSACONAZOLE Tablet 100 mg-MSD increased C max and AUC of tacrolimus (0,05 mg/kg single dose) by 121 % and 358 % respectively. When initiating POSACONAZOLE Tablet 100 mg-MSD treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose). Thereafter blood levels of tacrolimus should be monitored carefully during co-administration and upon discontinuation of POSACONAZOLE Tablet 100 mg-MSD, and the dose of tacrolimus should be adjusted as necessary.

Sirolimus: Repeat dose administration of oral posaconazole (400 mg oral suspension twice daily for 16 days) increased the C max and AUC of sirolimus (2 mg single dose) an average of 6,7-fold and 8,9-fold, respectively, in healthy subjects. When initiating therapy in patients already taking sirolimus, the dose of sirolimus should be reduced (e.g. to about 1/10 of the current dose) with frequent monitoring of sirolimus whole blood trough concentrations. Sirolimus concentrations should be performed upon initiation, during co-administration and at discontinuation of POSACONAZOLE Tablet 100 mg-MSD treatment, with sirolimus doses adjusted accordingly.

Rifabutin: NOXAFIL increased the C max and AUC of rifabutin by 31 % and 72 % respectively. Concomitant use of POSACONAZOLE Tablet 100 mg-MSD and rifabutin should be avoided unless the benefit to the patient outweighs the risk. If the drugs are co-administered, careful monitoring of full blood counts and adverse effects related to increased rifabutin levels (e.g. uveitis) is recommended.

Midazolam: Repeat dose administration of oral posaconazole (200 mg oral suspension twice daily for 7 days) increased the C max and AUC of IV midazolam (0,4 mg single dose) an average of 1,3 and 4,6-fold, respectively; NOXAFIL 400 mg oral suspension twice daily for 7 days increased the IV midazolam C max and AUC by 1,6 and 6,2-fold, respectively. Both doses of posaconazole increased C max and AUC of oral midazolam (2 mg single oral dose) by 2,2 and 4,5-fold, respectively. In addition, oral NOXAFIL (200 mg or 400 mg oral suspension) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to 8-10 hours during coadministration. It is recommended that dose adjustments of benzodiazepines metabolised by CYP3A4 be considered during co-administration with POSACONAZOLE Tablet 100 mg-MSD.

Zidovudine (AZT), lamivudine (3TC), indinavir: Clinical studies demonstrated that no clinically significant effects on zidovudine, lamivudine, indinavir were observed when administered with; POSACONAZOLE Tablet 100 mg-MSD therefore, no dose adjustments are required for these co-administered drugs.

HIV Protease Inhibitors: As HIV protease inhibitors are CYP3A4 substrates, it is expected that POSACONAZOLE Tablet 100 mg-MSD will increase plasma levels of these antiretroviral medicines. Repeat dose administration of oral posaconazole (400 mg oral suspension twice daily for 7 days) increased the C max and AUC of atazanavir (300 mg once a day for 7 days) an average of 2,6-fold and 3,7-fold, respectively, in healthy subjects. Repeat dose administration of NOXAFIL (400 mg oral suspension twice daily for 7 days) increased the C max and AUC of atazanavir to a lesser extent when administered as a boosted regimen with ritonavir (300 mg atazanavir plus ritonavir 100 mg once a day for 7 days) with an average of 1,5-fold and 2,5-fold, respectively, in healthy subjects. Frequent monitoring for adverse events and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with POSACONAZOLE Tablet 100 mg-MSD.

HMG-CoA reductase inhibitors primarily metabolised through CYP3A4: Repeat dose administration of oral NOXAFIL (50, 100, and 200 mg oral suspension once daily for 13 days) increased the C max and AUC of simvastatin (40 mg single dose) an average of 7,4- to 11,4-fold, and 5,7- to 10,6-fold, respectively. Increased HMG-CoA reductase inhibitor concentrations in plasma can be associated with rhabdomyolysis. Coadministration of posaconazole and HMG-CoA reductase inhibitors primarily metabolized through CYP3A4 is contraindicated. (see section 4.3)

Calcium channel blockers metabolised through CYP3A4: Frequent monitoring for adverse events and toxicity related to calcium channel blockers is recommended during co-administration with POSACONAZOLE Tablet 100 mg-MSD. Dose adjustment of calcium channel blockers may be required.

Digoxin: Administration of other azoles has been associated with increases in digoxin levels. Therefore, POSACONAZOLE Tablet 100 mg-MSD may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing POSACONAZOLE Tablet 100 mg-MSD treatment.

Venetoclax: Concomitant use of venetoclax (a CYP3A4 substrate) with Posaconazole increases venetoclax Cmax and AUC0-INF, which may increase venetoclax toxicities (see 4.4 Special Warnings and Special Precautions for Use).

Pregnancy

Studies in animals have shown reproductive toxicity. POSACONAZOLE Tablet 100 mg-MSD has been shown to cause skeletal malformations in rats at exposures lower than those obtained at therapeutic doses in humans. In rabbits POSACONAZOLE Tablet 100 mg-MSD was embryotoxic at exposures greater than those obtained at therapeutic doses. The potential risk to humans is unknown. POSACONAZOLE Tablet 100 mg-MSD should not be used during pregnancy.

Breastfeeding

POSACONAZOLE Tablet 100 mg-MSD is excreted into the milk of lactating rats. The excretion of POSACONAZOLE Tablet 100 mg-MSD in human breast milk has not been investigated. POSACONAZOLE Tablet 100 mg-MSD should not be used by breastfeeding mothers.

Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used.

Summary of the safety profile

POSACONAZOLE Tablet 100 mg-MSD: The safety of POSACONAZOLE Tablet 100 mg-MSD has been assessed in 230 patients enrolled in the pivotal clinical study. Patients were enrolled in a non-comparative pharmacokinetic and safety trial of POSACONAZOLE Tablet 100 mg-MSD when given as antifungal prophylaxis. Patients were immunocompromised with underlying conditions including haematological malignancy, neutropenia post-chemotherapy, Graft versus Host Disease (GVHD), and post HSCT. POSACONAZOLE Tablet 100 mg-MSDs therapy was given for a median duration of 28 days. Twenty patients received 200 mg daily dose and 210 patients received 300 mg daily dose (following twice daily dosing on Day 1 in each cohort). The most frequently reported treatment-related adverse reactions (u2265 5 %) with POSACONAZOLE Tablet 100 mg-MSD (300 mg once daily) were nausea and diarrhoea. The most frequently reported adverse reaction leading to discontinuation of POSACONAZOLE Tablet 100 mg-MSD 300 mg once daily was nausea. In addition, rare cases of torsade de pointes have been reported in patients taking POSACONAZOLE Tablet 100 mg-MSD.

Treatment-related adverse reactions (TRAEs) reported in POSACONAZOLE Tablet 100 mg-MSD and NOXAFIL Oral Suspension studies: The most common treatment-related adverse reactions reported in POSACONAZOLE Tablet 100 mg-MSD and NOXAFIL Oral Suspension studies across the whole population of healthy volunteers and patients are shown in Table 2.

Table 2: Treatment-related adverse reactions (TRAEs) reported in POSACONAZOLE Tablet 100 mg-MSDs and NOXAFIL Oral Suspension dosed subjects by body system n=2 400. Includes all TRAEs with incidence of 1 % or higher

Post-marketing experience

The following post-marketing adverse experience has been reported: Endocrine disorders: pseudoaldosteronism

There is no experience with overdosage of POSACONAZOLE Tablet 100 mg-MSD. POSACONAZOLE Tablet 100 mg-MSD is not removed by haemodialysis. Treatment is supportive and symptomatic.